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https://doi.org/10.1016/j.celrep.2021.109450SUMMARYImproving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-
molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have
demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019
(COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent thera-
pies or whether antibody therapies will remain efficacious against variants. Here, we show that a combination
of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h
after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC). Combining
RDV and antibodies provided a modest improvement in outcomes compared with single agents. These data
support the continued use of RDV to treat SARS-CoV-2 infections and the continued clinical development of
the C144 and C135 antibody combination to treat patients infected with SARS-CoV-2 variants.INTRODUCTION
A novel human coronavirus, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan,
China (Zhou et al., 2020b; Zhu et al., 2020) as the causative agent
of coronavirus disease 2019 (COVID-19). The spread of SARS-
CoV-2 was explosive with 140 million confirmed cases and >3
million deathsworldwide as of April 2021. Few therapies are avail-
able to treat COVID-19 in humans, and the rapid evolution of
SARS-CoV-2 variants threatens to diminish their efficacy. Remde-
sivir (RDV; Veklury) is the only US Food and Drug Administration
(FDA)-approved direct-acting, small molecule antiviral to treat
COVID-19. Prior to the emergence of SARS-CoV-2, RDV showed
broad-spectrum activity against highly pathogenic human CoVs,
including SARS-CoV,Middle East respiratory syndromecoronavi-
rus (MERS-CoV), their related enzootic viruses, and endemic
common-cold-causing CoV in various in vitro and in vivo preclin-
ical models of CoV pathogenesis (Brown et al., 2019; deWit et al.,
2020; Sheahan et al., 2017, 2020).More recently, RDVwas shown
to exert potent antiviral activity against SARS-CoV-2 in vitro
(Pruijssers et al., 2020) and therapeutic efficacy in a SARS-CoV-
2 rhesus macaque model, which recapitulates mild to moderate
respiratory symptoms (Williamson et al., 2020). In a double-blind,This is an open access article undrandomized, placebo-controlled trial (Adaptive COVID-19 Treat-
ment Trial [ACTT-1]), RDV was shown to shorten recovery time
in hospitalized COVID-19 patients by 5 days on average as
compared with those receiving placebo (Beigel et al., 2020). In
contrast, in an open-label, non-placebo-controlled, and non-
blinded clinical trial (WHO Solidarity trial), RDV was not shown
to improve outcomes in hospitalized patients (Wang et al.,
2020). Importantly,mutations in the viral RNA-dependent RNApo-
lymerase (RdRp) known to interfere with the antiviral activity of
RDV are not found in the SARS-CoV-2 variants of concern
(VOCs) (Martin et al., 2021). Because combinations of RDV with
immunomodulators (baricitinib) have very recently been shown
to improve COVID-19 outcomes over single-agent treatment (Kalil
et al., 2021), it remains unknown whether RDV combinations with
other antiviral drugswith complementarymodalitieswill yield simi-
larly promising results.
Several monoclonal antibodies (mAbs) targeting the SARS-
CoV-2 spike have been shown to potently neutralize SARS-
CoV-2 in vitro (Dieterle et al., 2020; Jones et al., 2020; Li et al.,
2021; Robbiani et al., 2020; Rogers et al., 2020; Yang et al.,
2020; Zost et al., 2020a, 2020b). mAb drugs targeting the
SARS-CoV-2 spike have demonstrated therapeutic efficacy in
multiple pre-clinical models of viral pathogenesis, and a selectCell Reports 36, 109450, July 27, 2021 ª 2021 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).




OPEN ACCESSfew have been authorized for emergency use by the FDA to
treat COVID-19 (Ly-CoV016/LyCoV555 [Eli Lilly]; REGN10987/
REGN10933 [Regeneron]) (ACTIV-3/TICO LY-CoV555 Study
Group, 2021; Barnes et al., 2020a, 2020b; Jones et al., 2020;
Schäfer et al., 2021). Most clinical candidate mAbs are RBD spe-
cific and have varying modes of binding and epitope specificities
(Barnes et al., 2020a). Lilly’s LY-CoV555 can recognize the RBD
in both the up and down conformations (Jones et al., 2020).
REGN10987 binds to the RBD outside the ACE2 binding site,
whereas REGN10933 binds to the top of the RBD and competes
with the ACE2 binding site (Hansen et al., 2020). Two recently
described highly potent SARS-CoV-2 neutralizing mAbs,
C144 and C135, are currently being evaluated in human
trials at the Rockefeller University Hospital (ClinicalTrials.gov:
NCT04700163) and licensed to Bristol Myers Squibb for devel-
opment (Robbiani et al., 2020). C144 (inhibitory concentration
at which 50% reduction is observed [IC50] = 2.55 ng/mL) and
C135 (IC50 = 2.98 ng/mL) were isolated from convalescent hu-
man patients and target non-overlapping sites on the receptor
binding domain (RBD) on the SARS-CoV-2 spike protein similar
to the REGNmAb cocktail (Barnes et al., 2020a, 2020b; Robbiani
et al., 2020; Schäfer et al., 2021). Because mAb prophylaxis can
prevent COVID-19, preliminary results from human clinical trials
evaluating the therapeutic efficacy of mAbs in COVID-19 outpa-
tients have thus far been promising (Weinreich et al., 2021; Zhou
et al., 2020b).
The emergence of SARS-CoV-2 variants that can partially or
completely evade mAbs in advanced clinical development is a
growing concern. For example, the SARS-CoV-2 South African
B.1.351 variant can completely evade neutralization by mAb LY-
CoV555 (Wang et al., 2021a, 2021b). Other mAbs in clinical devel-
opment, including the AstraZeneca COV2-2196 mAb and the Brii
BioSciences mAb Brii-198, have a reduction in neutralization po-
tency bymore than 6-fold as a result of the presence of the E484K
mutation (Chen et al., 2021; Wang et al., 2021b). Moreover, the
neutralization activity of the Regeneron mAb REGN10933 is also
dampened by the E484K mutation (Wang et al., 2021b). In
contrast, the variants do not affect the neutralization potency of
C135 (Wang et al., 2021b). Lastly, although the variants do not
affect the C144 + C135 antibody combination in vitro (Wang
et al., 2021c), it is not yet known if this mAb cocktail can protect
against the SARS-CoV-2 variants in vivo.
We previously developed a mouse-adapted model of SARS-
CoV-2 (SARS-CoV-2 MA10) pathogenesis based on the ancestral
pandemic strain (Leist et al., 2020). Following SARS-CoV-2 MA10
infection of standard laboratory mice, virus replicates primarily in
ciliated epithelial cells and type II pneumocytes with peak titers
by 48 h postinfection (hpi) concurrent with body weight loss, loss
of pulmonary function, the development of acute lung injury
(ALI), andmortality, consistent with severe humanCOVID-19 path-
ogenesis (Leist et al., 2020). Here, we define the prophylactic and
therapeutic efficacy of RDV and C144 + C135 mAbs used singly
and in combination in mice infected with SARS-CoV-2 MA10.
We show that the prophylactic and therapeutic administration of
RDV ormAb exert a robust antiviral effect, and their ability to abro-
gate diseasediminishedas a function of initiation time.Whencom-
bined, RDV/mAb therapy modestly improved outcomes
compared with monotherapy, suggesting that combination ther-2 Cell Reports 36, 109450, July 27, 2021apy may provide an additional therapeutic benefit over single
agents in humans with COVID-19. Importantly, we demonstrate
that C144 + C135 mAb combination protects from severe disease
against SARS-CoV-2 South African B.1.351 variant challenge in a
mouse model of age-related COVID-19 pathogenesis. These data
support the continued use of RDV to treat SARS-CoV-2 infections
and support the continued clinical development of the C144 and
C135 antibody combination to treat patients infected with SARS-
CoV-2 variants.
RESULTS
Prophylactic and therapeutic RDV protect against
COVID-19 in mice
First, we sought to determine the time at which RDV therapy
would fail to improve outcomes in SARS-CoV-2-infected mice.
Due to a serum esterase absent in humans but present in mice
that reduces RDV stability (carboxyesterase 1c [Ces1c]), we per-
formed all of our RDV efficacy studies in C57BL/6 mice that lack
this gene (Ces1c/) (Sheahan et al., 2017). Although we had
previously explored the in vivo efficacy of RDV against SARS-
CoV/SARS-CoV-2 chimeric viruses (Pruijssers et al., 2020), we
had not yet evaluated RDV in mice infected with our recently
described SARS-CoV-2 MA10 (Leist et al., 2020). We initiated
twice-daily treatment of mice with a human equivalent dose of
RDV (25 mg/kg) or vehicle 12 h prior to infection or 12 (early),
24 (mid-late), or 48 (late) hpi with 1 3 104 particle-forming units
(PFUs) of SARS-CoV-2 MA10. Body weight loss is a crude
marker of emerging CoV disease in mice. Body weight loss
observed in vehicle-treated animals was prevented with prophy-
lactic RDV (Figure 1A). When initiated after SARS-CoV-2 infec-
tion, only early therapeutic intervention (+12 h) was able to signif-
icantly diminish weight loss (Figure 1A). Although RDV therapy
initiated at 24 h did not prevent weight loss, lung viral load was
significantly diminished in this group similar to those receiving
prophylaxis (12 h) or early therapeutic intervention (+12 h) (Fig-
ure 1B). Similarly, lung discoloration, a gross pathologic feature
characteristic of severe lung damage, was observed in the
vehicle-treated animals but was diminished in all treatment
groups except the 48 hpi RDV group (Figure 1C). We then
used a histologic tool developed by the American Thoracic Soci-
ety (ATS) to quantitate the pathological features of ALI that we
recently utilized to examine the pulmonary pathology of SARS-
CoV-2 MA10-infected BALB/c mice (Leist et al., 2020; Matute-
Bello et al., 2011). Per animal, three random diseased fields in
lung tissue sections were blindly evaluated by a board-certified
veterinary pathologist for alveolar septal thickening, protein
exudate in the air space, hyaline membrane formation, and neu-
trophils in the interstitium or air spaces. Scoring revealed that
RDV prophylaxis and therapy initiated at both +12 and +24 hpi
reduced ALI as compared with vehicle-treated animals (Figures
1D and 2). A complementary histological tool measuring the
pathological hallmark of ALI, diffuse alveolar damage (DAD), re-
vealed consistent data (Figures 1E and 2) with those in Figure 1D
(Schmidt et al., 2018; Sheahan et al., 2020). Lastly, pulmonary
function was measured daily in a subset of mice per group
(n = 4) by whole-body plethysmography (WBP). As shown with
the WBP metric enhanced pause (PenH), a metric for airway
Figure 1. The prophylactic and therapeutic efficacy of RDV against SARS-CoV-2 in mice
(A)% starting weight in prophylactically treated mice with RDV at 12 h before infection and therapeutically at 12, 24, and 48 h postinfection (hpi). From left to right,
light blue bars denote12 h prophylactic treatment, orange bars denote +12 h therapeutic treatment, purple bars denote +24 h therapeutic treatment, aqua bars
denote +48 h therapeutic treatment, and gray bars denote vehicle-treated mice.
(B) Lung viral titers in prophylactically and therapeutically treated mice with RDV.
(C) Lung discoloration score in prophylactically and therapeutically treated mice with RDV.
(D and E) Lung pathology in prophylactically and therapeutically treated mice with RDV.
(F) Pulmonary function in prophylactically and therapeutically treatedmicewith RDV. p values are from a two-way ANOVA after Sidak’smultiple comparisons test.
LoD, limit of detection. Error bars denote min and max.




OPEN ACCESSresistance or obstruction that was previously validated in animal
models of CoV pathogenesis (Menachery et al., 2015; Sheahan
et al., 2017), only prophylactic and early therapeutic administra-
tion of RDV (+12 hpi) prevented the loss of pulmonary function
observed in the other groups. Together, these data show that
prophylactic and therapeutic RDV exert a profound antiviral ef-
fect when administered up to 24 hpi, but the ability of RDV ther-
apy to improve disease outcomes wanes with time of initiation.
Prophylactic and therapeutic single mAb and mAb
combinations reduce SARS-CoV-2 pathogenesis
In COVID-19 patients, the time at which mAb therapy loses its
protective effect remains unknown. To address this, we soughtto determine the prophylactic and therapeutic efficacy of a
cocktail of clinical candidate mAbs, C144 and C135, in the
SARS-CoV-2 MA10 pathogenesis model noted above. We first
established therapeutic efficacy profiles for single mAbs. We
treated C57BL/6 mice with mAb C144, mAb C135, or control
HIV mAb 12 h before infection or 12, 24, or 48 hpi with 1 3 104
PFUs of SARS-CoV-2 MA10 (Figures S1–S4). Both mAbs signif-
icantly prevented (prophylactic) or reduced (+12 h, +24 h) SARS-
CoV-2MA10 pathogenesis (bodyweight loss, lung discoloration,
ALI scores, etc.), with C135 exerting more robust protection over
C144 with measurable improvements in weight loss and
gross pathology even when initiated 48 hpi (Figures S1–S4). Un-
like C135 mAb, C144 mAb did not completely prevent virusCell Reports 36, 109450, July 27, 2021 3
Figure 2. Lung pathology of SARS-CoV-2-infected mice treated with RDV and vehicle prophylactically and therapeutically
Pathologic features of acute lung injury (ALI) were scored using two separate tools: the American Thoracic Society Lung Injury Scoring (ATS ALI) and the diffuse
alveolar damage (DAD) system. Using these systems, we created an aggregate score for the following features: neutrophils in the alveolar and interstitial space,
hyaline membranes, proteinaceous debris filling the air spaces, and alveolar septal thickening. Three randomly chosen high-power (360) fields of diseased lung
were assessed permouse. Representative images are shown from vehicle- and RDV-treatedmice. Symbols identifying example features of disease are indicated
in the figure. All images were taken at the same magnification. Scale bars indicate 100 mm.




OPEN ACCESSreplication in the lung when administered at 24 hpi, suggesting
incomplete viral breakthrough (Figure S3) likely driven by
mouse-adapting Q493K spike mutation, which resides in a re-
gion critical for C144 binding (Barnes et al., 2020a, 2020b; Gae-
bler et al., 2021; Leist et al., 2020). Neither antibody when
administered 48 hpi could prevent weight loss, lung discolor-
ation, or ALI, yet viral lung titers were significantly reduced (Fig-
ure S4). Together, these data demonstrate that clinical candidate
mAbs C135 and C144 can both prevent and significantly
diminish disease in an ongoing SARS-CoV-2 infection in mice.
Next, we evaluated the prophylactic and therapeutic efficacy
of combination C144 + C135 to determine if the single-agent
therapeutic efficacy could be improved with mAb combinations.
Similar to the studies with single-agent mAb, we treated
C57BL/6 mice with mAb combination C144 + C135 12 h prior
to or 12, 24, or 48 h after infection with 1 3 104 PFUs of SARS-4 Cell Reports 36, 109450, July 27, 2021CoV-2 MA10. Unlike the uniform and consistent body weight
loss observed in SARS-CoV-2 MA10-infected mice treated
with negative control HIV mAb, prophylactic, early (+12 h), and
mid-late (+24 h) therapeutic administration of C144 + C135
mAbs protected against body weight loss (Figure 3A). Initiation
of therapy 48 hpi afforded limited protection from body weight
loss (Figure 3A). Remarkably, the levels of infectious virus in
the lung were significantly reduced below the limit of detection
(50 PFUs) in all C144 +C135mAb groups by 5 days postinfection
(dpi), unlike control mAb-treated animals (mean lung titer = 1 3
104 PFUs/lobe). Mirroring the trend observed in body weight
loss, gross lung pathology as measured by observation of lung
discoloration was eliminated with prophylactic C144 + C135
mAb, significantly diminished with early (+12 h) and mid-late
(+24 h) dosing of C144 + C135 mAb, and even moderately
reduced with late (+48 h) therapy. We then quantitated the
Figure 3. The prophylactic and therapeutic efficacy of mAbs against SARS-CoV-2 in mice
(A) % starting weight in prophylactically treated mice with C144 + C135 at 12 h before infection and therapeutically at 12, 24, and 48 hpi. From left to right, light
blue bars denote 12 h prophylactic treatment, orange bars denote +12 h therapeutic treatment, purple bars denote +24 h therapeutic treatment, aqua bars
denote +48 h therapeutic treatment, and gray bars denote vehicle-treated mice.
(B) Lung viral titers in prophylactically and therapeutically treated mice with C144 + C135.
(C) Lung discoloration score in prophylactically and therapeutically treated mice with C144 + C135.
(D and E) Lung pathology in prophylactically and therapeutically treated mice with C144 + C135.
(F) Pulmonary function in prophylactically and therapeutically treated mice with C144 + C135. p values are from a two-way ANOVA after Sidak’s multiple
comparisons test. Error bars denote min and max.




OPEN ACCESShistologic features of ALI using the same tools employed in Fig-
ure 1, which demonstrated that prophylactic and therapy initi-
ated up to 24 hpi significantly reduced ALI observed in negative
control mAb-treated animals (Figures 3D and 4). When applying
the DAD scoring tool to the same tissue sections, we saw a
similar trend, yet only prophylactic and early therapeutic (+12
h) C144 + C135 significantly reduced scores (Figures 3E
and 4). In agreement with the histological assessment, loss of
pulmonary function observed in negative control mAb-treated
animals could be prevented with prophylactic and early thera-
peutic (+12 hpi) C144 + C135 (Figures 3F and 4). Interestingly,
combination mAb therapy initiated at 24 hpi also provided a
benefit in pulmonary function (Figures 3F and 4). Thus, mAb ther-apy can exert a profound antiviral effect even when administered
at later times postinfection.
Combination RDV/mAb cocktail demonstrates a small
improvement versus mAb therapy alone at 36 hpi
We sought to determine if combination RDV/C144 + C135 mAb
would further curtail viral pathogenesis over that provided by sin-
gle agents. We designed a study where we initiated single-agent
or combination therapy 24 h after SARS-CoV-2 MA10 infection,
treated mice up to 7 dpi, and followed mice until 12 dpi to deter-
mine if therapy accelerated recovery. Among groups receiving
single agents or combination therapies, significant differences
in body weight were not consistently noted (Figure S5A), but allCell Reports 36, 109450, July 27, 2021 5
Figure 4. Lung pathology of SARS-CoV-
2-infected mice treated with C144 + C135
and an HIV mAb prophylactically and
therapeutically
Pathologic features of ALI were scored using two
separate tools: ATS ALI and diffuse alveolar dam-
age (DAD). Using these systems, we created an
aggregate score for the following features: neu-
trophils in the alveolar and interstitial space, hya-
linemembranes, proteinaceous debris filling the air
spaces, and alveolar septal thickening. Three
randomly chosen high-power (360) fields of
diseased lung were assessed per mouse. Repre-
sentative images are shown from HIV mAb and
C144 + C135-treated mice. Symbols identifying
example features of disease are indicated in the
figure. All images were taken at the same magni-
fication. Scale bars indicate 100 mm.




OPEN ACCESStherapeutic treatment groups provided complete protection
from mortality observed with vehicle treatment (Figure S5B).
Upon completion of the study on 12 dpi, differences in gross pa-
thology were not noted among treatment groups (Figure S5C).
We performed pulmonary function by WBP on select groups
(i.e., vehicle/control mAb and RDV/mAb combination) for the first
5 days of infection and observed a rapid improvement in pulmo-
nary function with combination therapy that returned to baseline
by 3 dpi (Figure S5D).
To determine if a further delay in treatment initiation time closer
to peak of virus replication in the lung would reveal an improved
benefit of combination therapy, we performed a therapeutic effi-
cacy study initiating treatment at 36 hpi. Rather than focus on the6 Cell Reports 36, 109450, July 27, 2021potential effects on recovery, the goal of
this study was to determine if combina-
tion therapy had a differential effect on
lung pathology and virus replication dur-
ing the acute phase of disease. We
initiated treatment 36 hpi with 1 3 104
PFUs SARS-CoV-2 MA10 in C57BL/6
(Ces1c/) mice with the vehicle, single-
agent, and combination groups as
described in the previous combination
experiment. We observed a small but
measurable improvement in body weight
loss with RDV/mAb treatment (Figure 5A).
Similarly, by 3 dpi, only the RDV/control
mAb and RDV/mAb-treated groups had
lower lung viral titers compared with the
vehicle/control mAb-treated group (Fig-
ure 5B). By 5 dpi, vehicle-treated animals
had mean lung titers nearing 1 3 105
PFUs, yet all treatment groups had signif-
icantly reduced lung titers at or near the
limit of detection (Figure 5C). When exam-
ining gross lung pathology 5 dpi, all thera-
pies provided significant protection from
lung discoloration observed with vehicle
treatment, but RDV/mAb combination
therapy group had the overall lowestscore and was significantly improved over single-agent
vehicle/mAb (Figure 5D). We then quantitated the histological
manifestations of ALI using the two complementary scoring tools
employed above. With both ATS and DAD scoring systems, ALI
was readily apparent in vehicle-treated animals (Figures 5E and
5F). Althoughmirroring the trend observed in the gross patholog-
ical observations where combination therapy afforded protec-
tion over single-agent therapy, significant differences were not
observed among groups receiving antiviral therapies, and all
reduced ALI on 5 dpi (Figures 5E and 5F). Lastly, we examined
the effect of combination therapy on pulmonary function. Com-
bination RDV/mAb initiated at 36 hpi reduced the loss of pulmo-
nary function observed with vehicle treatment on 3–5 dpi
Figure 5. The therapeutic efficacy of RDV and
mAbs as single agents and in combination at
36 hpi in SARS-CoV-2-infected mice
(A) % starting weight in therapeutically treated mice with
vehicle + HIV mAb, vehicle + C144 + C135, RDV + HIV
mAb, and RDV +C144 + C135 at 36 hpi. From left to right,
gray bars denote vehicle/control mAb-treated mice, yel-
low bars denote vehicle/mAb therapeutic treatment, blue
bars denote RDV/control mAb therapeutic treatment, and
orange bars denote RDV/mAb therapeutic treatment.
(B) Day 3 postinfection lung viral titers in therapeutically
treated mice with single agents and combination therapy.
(C) Day 5 postinfection lung viral titers in therapeutically
treated mice with single agents and combination therapy.
(D) Lung discoloration scores in therapeutically treated
mice with single agents and combination therapy.
(E and F) Lung pathology in therapeutically treated mice
with single agents and combination therapy.
(G) Pulmonary function in therapeutically treated mice
with vehicle + HIV mAb and RDV + C144 + C135. p values
are from a two-way ANOVA after Sidak’s multiple com-
parisons test. Error bars denote min and max.
Veh., vehicle treatment.
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OPEN ACCESS(Figure 5G). Altogether, our findings suggest that combination
therapy with RDV and potent neutralizing mAbs provides a small
but measurable benefit over single agents in some, but not all,
metrics of SARS-CoV-2 pathogenesis in this model.
C144 + C135 mAb prophylaxis and therapy improve
outcomes in South African B.1.351 VOC-infected mice
The emergence of neutralization-resistant SARS-CoV-2 variants
is a growing threat. B.1.351, which initially emerged in South Af-
rica, is a VOC that can infect mice without adaptation (Montagu-
telli et al., 2021). B.1.351 has characteristic RBD mutations at
residues K417, E484, and N517, which result in resistance to
many of the class 1 and 2 antibodies that dominate the initial
RBD-directed neutralizing response (Barnes et al., 2020a;
Chen et al., 2021; Planas et al., 2021; Wang et al., 2021c). For
example, B.1.351 is completely resistant to Eli Lilly’s Ly-
CoV555 mAb (Wang et al., 2021a), underlining the importance
of monitoring the in vivo efficacy of mAb therapies that are in
advanced clinical testing against SARS-CoV-2 VOCs. To
examine the in vivo efficacy of the C144 + C135 mAb combina-
tion against recombinant mouse-adapted SARS-CoV-2 bearing
the B.1.351 spike, we treated aged BALB/c mice with mAb 12 h
before or after infection with 13 104 PFUs.Weight loss observed
with control antibody treatment was prevented with C144 +
C135 prophylaxis, and lung viral loads were reduced below the
limit of detection on both 3 and 5 dpi (Figures 6A–6C). Similarly,
mAb combination therapy accelerated recovery and diminished
virus replication below the limit of detection by 5 dpi (Figures 6A
and 6C). To complement the infectious virus data, we then quan-
titated viral subgenomic RNAs in mouse lung tissues in each
group. Unlike the quantitation of SARS-CoV-2 genomic RNA,
which has the potential to measure RNA from infectious parti-
cles, defective particles, mAb-bound particles, and various repli-
cative forms of viral RNA, these subgenomic RNA qRT-PCR
assays are specific for envelope (E) and nucleocapsid (N) viral
transcripts that are made only in actively replicating cells. Pro-
phylactic and therapeutic administration of C144 + C135 signif-
icantly reduced lung viral E subgenomic mRNA (sgRNA) (Figures
6D and 6E) and N sgRNA (Figures 6F and 6G) compared with the
control mAb-treated animals, indicating that mAb therapy suc-
cessfully reduced levels of replication of SARS-CoV-2 bearing
the B.1.351 spike in vivo. Finally, gross pathology caused by
mouse-adapted SARS-CoV-2 bearing the B.1.351 spike was
significantly reduced in aged mice with both prophylactic and
therapeutic administration of the C144 + C135 combination (Fig-
ures 6H and 6I). Collectively, these data demonstrate that both
prophylaxis and therapy with combination C144 + C135 mAb
can potently reduce virus replication and improve disease out-
comes in vivo following infection with variant B.1.351.
DISCUSSION
Therapies effective against the current and future SARS-CoV-2
VOCs are desperately needed to treat those yet to be vaccinated
or those experiencing breakthrough infection. RDV is a broad-
spectrum antiviral drug and has potent antiviral activity against
multiple emerging, endemic, and enzootic CoVs, including
SARS-CoV, SARS-CoV-2, MERS-CoV, bat-CoV WIV-1, bat-8 Cell Reports 36, 109450, July 27, 2021CoV RsSHC014, bat-CoV HKU5, bat-CoV HKU-3-1, HCoV-
229, HCoV-NL63, HCoV-OC43, and porcine deltacoronavirus
(PDCoV) (Agostini et al., 2018; Brown et al., 2019; de Wit et al.,
2020; Sheahan et al., 2017). In addition to the in vitro activity of
RDV against SARS-CoV-2 (Pruijssers et al., 2020), RDV can exert
an antiviral effect and diminish SARS-CoV-2 disease in rhesus
macaques that develop mild respiratory disease (Williamson
et al., 2020). Similarly, the prophylactic efficacies of mAbs
C144 and C135 have previously been evaluated in replication
models of mouse-adapted SARS-CoV-2 based on the ancestral
pandemic strain (Schäfer et al., 2021), but their prevention and
therapy have not yet been evaluated in the context of the
emerging variants that can evade vaccine-elicited antibodies
and existing mAb therapies.
Human clinical data for direct antivirals like mAb and small
molecule antivirals like RDV provide clear evidence that their
success at improving outcomes is directly related to the time af-
ter the onset of symptoms that therapy is initiated. Outpatient
studies evaluating mAb drugs in humans with mild to moderate
COVID-19 demonstrated notable reductions in virus shedding
and symptoms, which enabled the FDA emergency use authori-
zation (EUA) of both Eli Lilly’s and Regeneron’s antibody cock-
tails (Chen et al., 2020; Gottlieb et al., 2021; Weinreich et al.,
2021). However, hospitalized patients with advanced COVID-
19 treated with these mAb drugs did not have measurably
improved outcomes compared with standard of care (ACTIV-3/
TICO LY-CoV555 Study Group, 2021). Although RDV has been
shown to accelerate recovery of COVID-19 hospitalized patients
(Beigel et al., 2020), insight into whether RDV will further improve
outcomes in patients earlier in the course of COVID-19 remains
unknown. Thus, the optimal window after the onset of symptoms
within which to treat with antivirals such as RDV or potent mAbs
remains unknown.
In this study, we aimed to define the time after SARS-CoV-2
infection in mice where RDV or mAb therapy fail to exert an anti-
viral effect and/or fail to improve disease outcomes. Likemouse-
adapted models of SARS-CoV and MERS-CoV, the replication
kinetics of mouse-adapted SARS-CoV-2 MA10 in mice is com-
pressed with peak replication in the lung 48 hpi (Leist et al.,
2020). In contrast, the replication kinetics of SARS-CoV-2 in
the airways of humans is more variable with reports estimating
peak replication within the first week after the onset of symptoms
(Liu et al., 2020; Zheng et al., 2020). Moreover, human patients
can shed viral RNA in the mucosa of the upper respiratory tract
as long as 24 dpi (Zhou et al., 2020a), underlining that sustained
viral shedding and symptoms can last considerably longer in hu-
mans than in mice. Thus, the window within which to intervene
with antiviral therapy prior to the peak of virus replication in hu-
mans is dramatically different from in mice (2 days). Although
our mousemodel faithfully recapitulates many aspects of human
COVID-19 (e.g., high titer replication in the upper and lower air-
ways, loss of pulmonary function, ALI, age-related exacerbation
of disease, etc.), it is not possible to very finely correlate the com-
pressed kinetics of disease in mouse and those in humans, but
there are a few notable takeaways from the modeling presented
herein. Given early therapeutic treatment at +12 and +24 hpi in
ourmodel provided themost benefit, it is likely the benefit of anti-
body and small molecule antivirals like RDV will be maximized if
Figure 6. The prophylactic and therapeutic efficacy of C144 + C135 against SARS-CoV-2 B.1.351 in aged mice
(A) % starting weight in prophylactically treated mice with C144 + C135 at 12 h before infection and therapeutically at 12 hpi. From left to right, light blue bars
denote 12 h prophylactic treatment, orange bars denote +12 h therapeutic treatment, and gray bars denote prophylactically treated mice with HIV mAb.
(B and C) Lung viral titers at days 3 and 5 postinfection in prophylactically and therapeutically treated mice with C144 + C135 and HIV mAb negative controls.
(D and E) Subgenomic envelope (E) RNA copies/lobe in prophylactically and therapeutically treated mice with C144 + C135 and HIV mAb.
(F and G) Subgenomic nucleocapsid (N) RNA copies/lobe in prophylactically and therapeutically treated mice with C144 + C135 and HIV mAb.
(H and I) Lung discoloration at days 3 and 5 postinfection in prophylactically and therapeutically treated mice with C144 + C135 and HIV mAb. p values are from a
one-way ANOVA following Dunnett’s multiple comparisons. Error bars denote min and max.




OPEN ACCESSgiven prior to peak viral replication and/or early in the disease
course before patients are hospitalized. In addition, we show a
small improvement with combination mAb/RDV over single-
agent therapy, which suggests that combinations of antiviral
drugs of disparate modalities may offer an additional benefit in
COVID-19 patients over single agents, something that should
be rigorously evaluated in humans. Although our studies clearly
support the use/evaluation of RDV and mAb as treatments for
COVID-19, both are administered intravenously, limiting their
broad distribution to COVID-19 outpatients. Potential strategies
to allow the wider dissemination of these treatments may include
chemical alteration of RDV to facilitate oral bioavailability and/or
less complicated subcutaneous or intramuscular injections ofmAbs. The effect of mAb injection route (i.e., subcutaneous
versus intravenous) on pharmacokinetics and safety is currently
being evaluated for C144 and C135 in phase 1 clinical studies
(ClinicalTrials.gov: NCT04700163).
Given the growing emergence of SARS-CoV-2 variants, we
examined the prophylactic and therapeutic efficacy of the
C144 + C135 combination against the South African B.1.351
variant spike in a robust age-related mouse model of SARS-
CoV-2 pathogenesis. Importantly, the C144 + C135 cocktail
demonstrated prophylactic and therapeutic efficacy against
the B.1.351 VOC, which is encouraging given that this variant
has demonstrated full escape from other mAbs approved for
emergency use in humans, such as the LY-CoV555. In addition,Cell Reports 36, 109450, July 27, 2021 9




OPEN ACCESSthe neutralizing potency of the AstraZeneca and Brii Biosciences
mAbs in clinical trials are clearly dampened bymutations present
in the variants, such as the B.1.351 (Wang et al., 2021b). The
target of the antiviral activity of RDV is the viral RdRp. Impor-
tantly, hallmark mutations of current SARS-CoV-2 VOCs are
not found in regions of the RdRp known to affect the antiviral po-
tency of RDV; thus, antiviral resistance to RDV is not currently
anticipated with current VOCs (Martin et al., 2021). In the context
of emerging variants in the future, it will be critical to continue to
evaluate the prevention and therapy of currently approved small
molecule and mAb antivirals and those in clinical development
against newly emerging variants of interest. Our results reveal
that prophylaxis and therapy with the C144 + C135 mAb combi-
nation has high efficacy against the B.1.351 VOC spike in vivo
and can diminish the development of disease during an ongoing
SARS-CoV-2 infection in mice. These data support the further
evaluation of this mAb cocktail as therapy in human patients in-
fected with the B.1.351 variant.Limitations of this study
Although mice are a robust pathogenesis small-animal model for
COVID-19, their infection time course and time to peak lung viral
replication are compressed relative to the infection time course
of humans. Although this study suggests that early treatment
with SARS-CoV-2 antivirals and mAbs is critical for best disease
outcomes, it does not inform which specific time points may be
targeted for interventions in humans. Moreover, the mice used in
our mAb studies did not have humanized Fc receptors, which
likely play a role in protection and/or pathogenesis in the context
of COVID-19. Additional animal models may be used to help
clarify these questions.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals and virus infections
Twenty-week-old male and female Ces1c (/) on a B6 background (C57BL/6J: Jackson Laboratory # 014096) and twenty-week-old
female on a B6 background (C57BL6J: Jackson Laboratory # 000664) were purchased from Jackson Laboratory. Eleven-month-old
female BALB/c mice were purchased from Envigo (#047). A mouse-adapted SARS-CoV-2 virus (MA10) was used in all experiments
and this virus was previously described (Leist et al., 2020). Briefly, mutations predictive of increased affinity to mouse ACE2
were introduced into a SARS-CoV-2 virus plasmid system and the virus was recovered by reverse genetics (Dinnon et al., 2020).
This modified virus was then serially passaged in aged BALBc mice (Envigo #047) for ten passages which we refer to as the
mouse-adapted passage 10 (MA10) SARS-CoV-2 (Leist et al., 2020). A mouse-adapted (MA10) backbone expressing the SARS-
CoV-2 B.1.351 spike was generated for this study. All mice were anesthetized and infected with SARS-CoV-2 MA10 or B.1.351
spike/MA10 intranasally with 13 104 PFU/ml. Mice were weighed daily and weremonitored for signs of SARS-CoV-2 clinical disease
in all experiments.
Animal care
The study was carried out in accordance with the recommendations for care and use of animals by the Office of Laboratory Animal
Welfare (OLAW), National Institutes of Health and the Institutional Animal Care and Use Committee (IACUC) protocol number: 20-059
at University of North Carolina (UNC permit no. A-3410-01). Virus inoculations were performed under anesthesia and all efforts were
made to minimize animal suffering. Animals were housed in groups and fed standard chow diets.
METHOD DETAILS
Study design and treatment groups
For the RDV experiment, a total of n = 40, 20-week-old male and female mice were divided into four groups each with n = 10 mice
with equal numbers of females and males in each group. RDV was administered subcutaneously twice per day (BID) at 25 mg/kg.
Groups of n = 10 mice (n = 5 males and n = 5 females) were used in either the prophylaxis12 hours before infection group, the early
therapeutic 12 hours post infection group, the mid-late therapeutic 24 hours post infection group, and the late therapeutic 48 hours
post infection group.
For the initial monoclonal antibody experiment, mice were infected as described above and weighed daily and were monitored for
signs of SARS-CoV-2 clinical disease. A total amount of 200 mg of C144 + C135, 200 mg of C144, 200 mg of C135, and 200 mg of HIV
mAbs 3BC117 + 10-1074 was administered intraperitonially once by injection for each intervention group. Groups of n = 20 female
mice (n = 5 mice treated with C144 + C135, n = 5 mice treated with C144, n = 5 mice treated with C135, and n = 5 mice treated with
3BNC117 + 10-1074) were administered antibody 12 hours before infection, n = 20 femalemice (n = 5mice treated with C144 +C135,
n = 5 mice treated with C144, n = 5 mice treated with C135, and n = 5 mice treated with 3BNC117 + 10-1074) were administered
antibody 12hpi (early therapeutic group), n = 20 female mice (n = 5 mice treated with C144 + C135, n = 5 mice treated with C144,
n = 5 mice treated with C135, and n = 5 mice treated with 3BNC117 + 10-1074) were administered antibody 24hpi (mid-late thera-
peutic group), and n = 20 female mice (n = 5 mice treated with C144 + C135, n = 5 mice treated with C144, n = 5 mice treated with
C135, and n = 5 mice treated with 3BNC117 + 10-1074) were administered antibody 48hpi (late therapeutic group).
For the 24hpi drug andmAbcombination intervention experiment, a total of n = 40,20-week-oldmale and femalemicewere divided
into four groups eachwith n = 10micewith equal numbers of females andmales in each group. At 24hpi, RDV treatmentwas initiated by
subcutaneous injection twice per day (BID) at 25mg/kg, and a total amount of 200 mg of C144 +C135was administered intraperitonially
once by injection. n = 10mice (n = 5males and n= 5 females) were used in the vehicle +HIVmAbgroup. n = 10mice (n = 5males and n =
5 females) were used in the vehicle + C144 + C135mAb group. n = 10mice (n = 5males and n = 5 females) were used in the RDV + HIV
mAb group. n = 10 mice (n = 5 males and n = 5 females) were used in the RDV + C144 + C135 mAb group.
For the 36hpi drug +mAb combination intervention experiment, a total of n = 64,20-week-oldmale and femalemice were divided
into four groups each with n = 16 mice with an equal number of females and males in each group. At 36hpi, RDV treatment was initi-
ated by subcutaneous injection twice per day (BID) at 25 mg/kg, and a total of 200 mg of each monoclonal antibody treatment was
administered intraperitonially once by injection. n = 32 mice were harvested at d3pi to evaluate early lung viral replication titers, and
remaining mice were harvested at d5pi. n = 16 mice (n = 8 males and n = 8 females) were used in the vehicle + HIV mAb group. n = 16
mice (n = 8 males and n = 8 females) were used in the vehicle + C144 + C135 mAb group. n = 16 mice (n = 8 males and n = 8 females)
were used in the RDV +HIVmAb group. n = 16mice (n = 8males and n = 8 females) were used in the RDV +C144 + C135mAb group.e2 Cell Reports 36, 109450, July 27, 2021




OPEN ACCESSFinally, for the B.1.351 VOC experiment we used n = 10 aged BALB/c females in the HIV mAb control prophylaxis group, n = 10
aged BALB/c females in the C144 + C135mAb combination prophylaxis group, and n = 10 aged BALB/c females in the C144 + C135
combination therapeutic group.
Lung pathology scoring
Acute lung injury was quantified via two separate lung pathology scoring scales: Matute-Bello and Diffuse Alveolar Damage (DAD)
scoring systems. Analyses and scoring were performed by a Board Certified Veterinary Pathologist whowas blinded to the treatment
groups as described previously (Sheahan et al., 2020). Lung pathology slides were read and scored at 600X total magnification.
The lung injury scoring system used is from the American Thoracic Society (Matute-Bello) in order to help quantitate histological
features of ALI observed in mouse models to relate this injury to human settings. In a blinded manner, three random fields of lung
tissue were chosen and scored for the following: (A) neutrophils in the alveolar space (none = 0, 1–5 cells = 1, > 5 cells = 2), (B) neu-
trophils in the interstitial septae (none = 0, 1–5 cells = 1, > 5 cells = 2), (C) hyaline membranes (none = 0, one membrane = 1, > 1mem-
brane = 2), (D) Proteinaceous debris in air spaces (none = 0, one instance = 1, > 1 instance = 2), (E) alveolar septal thickening (< 2x
mock thickness = 0, 2–4x mock thickness = 1, > 4x mock thickness = 2). To obtain a lung injury score per field, A–E scores were put
into the following formula score = [(20x A) + (14 x B) + (7 x C) + (7 x D) + (2 x E)]/100. This formula contains multipliers that assign
varying levels of importance for each phenotype of the disease state. The scores for the three fields per mouse were averaged to
obtain a final score ranging from 0 to and including 1.
The second histology scoring scale to quantify acute lung injury was adopted from a lung pathology scoring system from lung RSV
infection in mice (Schmidt et al., 2018). This lung histology scoring scale measures diffuse alveolar damage (DAD). Similar to the imple-
mentation of the ATS histology scoring scale, three random fields of lung tissue were scored for the following in a blinded manner: 1 =
absence of cellular sloughing and necrosis, 2 = Uncommon solitary cell sloughing and necrosis (1–2 foci/field), 3 = multifocal (3+foci)
cellular sloughing and necrosiswith uncommon septal wall hyalinization, or 4 =multifocal (> 75%of field) cellular sloughing and necrosis
with common and/or prominent hyaline membranes. The scores for the three fields per mouse were averaged to get a final DAD score
per mouse. The microscope images were generated using an Olympus Bx43 light microscope and CellSense Entry v3.1 software.
Remdesivir (RDV)
RDV was synthesized at Gilead Inc., and its chemical composition and purity were analyzed by nuclear magnetic resonance, high
resolution mass spectrometry, and high-performance liquid chromatography. RDV was solubilized in 12% sulfobutylether-b-cyclo-
dextrin in water (with HCl/NaOH) at pH 5 for in vivo studies in mice. RDV was made available to UNC Chapel Hill under an existing
material transfer agreement with Gilead Sciences Inc.
RNA extraction and subgenomic RNA assay
Lung lobes were harvested and homogenized in 1ml of TRIzol reagent. RNA was extracted with phenol/chloroform/isoamyl alcohol
solution (25:24:1), precipitated with isopropyl alcohol, washed with 75% ethanol, and resuspended in RNAase-free water. SARS-
CoV-2 E gene and N gene sgRNA was measured by a one-step RT-qPCR adapted from previously described methods (Li et al.,
2021). RNA extracted from animal samples or RNA standards were then measured using TaqMan Fast Virus 1-Step Master Mix
(ThermoFisher, catalog # 4444432) and custom primers/probes targeting the E gene sgRNA (forward primer: 50 CGATCTCTTGTA
GATCTGTTCTCE 30; reverse primer: 50 ATATTGCAGCAGT ACGCACACA 30; probe: 50 FAM ACACTAGCCATCCTTACTGCGC
TTCG-BHQ1 30) or the N gene sgRNA (forward primer: 50 CGATCTCTTGTAGATCTGTTCTC 30; reverse primer: 50 GGTGAA CCAAGA
CGCAGTAT 30; probe: 50 FAM-TAACCAGAATGGAGAACGCAGTGGG-BHQ1 30). RT-QPCRreactions were carried out on a CFX Opus
384 machine (Bio-Rad) using a program below: reverse transcription at 50C for 5 minutes, initial denaturation at 95C for 20 s, then 40
cycles of denaturation-annealing-extension at 95C for 15 s and 60C for 30 s. Standard curveswere used to calculate E or N sgRNA in
copies per ml; the limit of detections (LOD) for both E and N sgRNA assays were 150 copies per lung lobe.
Biocontainment and biosafety
Studies were approved by the UNC Institutional Biosafety Committee approved by animal and experimental protocols in the Baric
laboratory. All work described here was performed with approved standard operating procedures for SARS-CoV-2 in a biosafety
level 3 (BSL-3) facility conforming to requirements recommended in the Microbiological and Biomedical Laboratories, by the U.S.
Department of Health and Human Service, the U.S. Public Health Service, and the U.S. Center for Disease Control and Prevention
(CDC), and the National Institutes of Health (NIH).
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed usingGraphPad Prism 9. Statistical tests used in each figure are denoted in the corresponding
figure legend. A Sidak’s multiple comparisons test was used following 2-way ANOVAs and this is also denoted in the figure legends.Cell Reports 36, 109450, July 27, 2021 e3
